Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

JA Bernstein, JC Virchow, K Murphy, JF Maspero, J Jacobs, Y Adir, M Humbert, M Castro, DA Marsteller, J McElhattan, L Hickey, M Garin, R Vanlandingham, Guy Brusselle

Research output: Contribution to journalArticleAcademicpeer-review

56 Citations (Scopus)
Original languageEnglish
Pages (from-to)461-474
Number of pages14
JournalThe Lancet Respiratory Medicine
Issue number5
Publication statusPublished - 2020

Research programs

  • EMC MM-04-42-02

Cite this